Trials / Recruiting
RecruitingNCT07100080
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 596 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iza-bren | Specified dose on specified days |
| DRUG | Carboplatin | Specified dose on specified days |
| DRUG | Cisplatin | Specified dose on specified days |
| DRUG | Pemetrexed | Specified dose on specified days |
Timeline
- Start date
- 2025-11-05
- Primary completion
- 2028-09-15
- Completion
- 2031-05-15
- First posted
- 2025-08-03
- Last updated
- 2026-04-16
Locations
186 sites across 25 countries: United States, Argentina, Belgium, Canada, Chile, China, Colombia, France, Germany, Greece, India, Italy, Japan, Mexico, Netherlands, Norway, Poland, Romania, Singapore, South Korea, Spain, Switzerland, Taiwan, Thailand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07100080. Inclusion in this directory is not an endorsement.